Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance

FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us

@CircRes Review Alert! Mechanisms of #CardiovascularToxicities Associated with #Immunotherapies. Learn more at

@baik_alan @CardioOncology

Congratulations to @JuanQinMed in representing the Moslehi Lab & @VUMChealth @VUMC_heart #CardioOnc program at the International Cardio-Oncology Forum in China! @VUMCResearch

Watching the #AACR21 session on ICI-induced autoimmunity and want to learn more about modeling immune-related adverse events? Check out this recent @CD_AACR paper by Spencer Wei, @WCFWMeijers, @CardioOncology, Jim Allison and colleagues

A+ job by @IsikCards & @SarjuGanatraMD in discussing TKI-associated vascular disease. Such diverse vascular effects by BCR-ABL inhibitors! Does the "ABCDE" steps for cardiovascular health apply to all CML patients? #ACC21 @u_campia @DrTochiOkwuosa @baik_alan @Dr_Mike_Fradley